Table 3.
Exploratory univariate analysis of factors to predict PFS and OS.
| Parameter | No. of patients(%) | Univariate analysis for PFS | Univariate analysis for OS | ||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | ||
| Sex | 1.023 | 0.635-1.647 | 0.926 | 1.044 | 0.587-1.854 | 0.844 | |
| Male | 36 (50.0) | ||||||
| Female | 36 (50.0) | ||||||
| Age | 0.592 | 0.335-1.048 | 0.072 | 0.679 | 0.345-1.335 | 0.262 | |
| <65 | 53 (73.6) | ||||||
| ≥65 | 19 (26.4) | ||||||
| Treatment program | 0.829 | 0.509-1.351 | 0.452 | 0.815 | 0.453-1.464 | 0.493 | |
| RS | 42 (58.3) | ||||||
| FS | 30 (41.7) | ||||||
| Primary tumor site | 0.742 | 0.417-1.322 | 0.311 | 0.852 | 0.426-1.704 | 0.651 | |
| Left colon | 54 (75.0) | ||||||
| Right colon | 16 (22.2) | ||||||
| Liver metastasis | 0.642 | 0.387-1.065 | 0.086 | 0.478 | 0.255-0.894 | 0.021 | |
| Yes | 44 (61.1) | ||||||
| No | 28 (38.9) | ||||||
| KRAS | 1.070 | 0.646-1.772 | 0.794 | 0.875 | 0.473-1.620 | 0.671 | |
| Wide type | 32 (44.4) | ||||||
| Mutant | 32 (44.4) | ||||||
| MPV | 1.144 | 0.703-1.861 | 0.589 | 0.808 | 0.451-1.446 | 0.473 | |
| <9.9 | 43 (59.7) | ||||||
| ≥9.9 | 29 (40.3) | ||||||
| NLR | 0.933 | 0.550-1.584 | 0.798 | 1.662 | 0.855-3.231 | 0.134 | |
| <2.15 | 21 (29.2) | ||||||
| ≥2.15 | 51 (70.8) | ||||||
| LDH | 1.332 | 0.760-2.333 | 0.316 | 1.698 | 0.885-3.257 | 0.111 | |
| <312 | 55 (76.4) | ||||||
| ≥312 | 17 (23.6) | ||||||
| D-Dimer | 1.320 | 0.809-2.154 | 0.267 | 1.288 | 0.726-2.287 | 0.387 | |
| <0.89 | 45 (62.5) | ||||||
| ≥0.89 | 27 (37.5) | ||||||
MPV, Mean Platelet Volume; NLR, Neutrophil-to-Lymphocyte Ratio; LDH, lactate dehydrogenase. Bold values: P<0.05.